ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (27)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gutierrez, J.P.
Right arrow Articles by Phelan, P.D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gutierrez, J.P.
Right arrow Articles by Phelan, P.D.
Eur Respir J 2001; 17:281-286
Copyright ©ERS Journals Ltd 2001

Interlobar differences in bronchoalveolar lavage fluid from children with cystic fibrosis

J.P. Gutierrez1, K. Grimwood3, D.S. Armstrong1, J.B. Carlin2, R. Carzino3, A. Olinsky1, C.F. Robertson1 and P.D. Phelan2,3

1 Dept of Respiratory Medicine and the 2 Clinical Epidemiology and Biostatistics Unit, Murdoch Children's Research Institute, and 3 Dept of Paediatrics, University of Melbourne, Parkville, Victoria, 3052, Australia

CORRESPONDENCE: K. Grimwood, Dept of Paediatrics, Wellington School of Medicine, PO Box 7343, Wellington, 6015, New Zealand. Fax: 64 43855898

Keywords: bacteria, bronchoalveolar lavage, child, cystic fibrosis, inflammation

Received: May 12, 2000
Accepted October 18, 2000

This study was supported by grants from the Murdoch Children's Research Institute and the JB Were Charitable Fund, Melbourne, Australia.


   Abstract
TOP
 Abstract
Methods
 Results
 Discussion
 Acknowledgements
 References
 
Bronchoalveolar lavage (BAL) performed in specialist centres has improved the understanding of infant cystic fibrosis (CF) lung disease. As most researchers sample from a single lobe, it was determined whether BAL results could be generalized to other lung segments.

Thirty-three CF children, aged 1.5–57 months, underwent in random order sequential BAL of their right middle and lingula lobes. Specimens from each lobe had separate quantitative bacteriology, cytology and cytokine analysis.

Bacterial counts ≥1x105 colony forming units (cfu)·mL–1 were observed in nine (27%) subjects, including six involving only the right middle lobe. These six children had similar inflammatory indices in their right middle and lingula lobes, and interleukin (IL)-8 concentrations in the latter were significantly higher than that observed within the lingula lobes of the 24 CF children with bacterial counts <1x105 cfu·mL–1. Lingula neutrophil and IL-8 levels correlated best with right middle lobe bacteria numbers.

This observational study in cystic fibrosis children suggests that while inflammation is detected in both lungs, bacterial distribution may be more inhomogeneous. Bronchoalveolar lavage microbiological findings from a single lobe may therefore, not be generalized to other lung segments. When performing bronchoalveolar lavage in cystic fibrosis children, it is important to sample from multiple sites.

While the lungs of newborn infants with cystic fibrosis (CF) are initially normal 1, changes in structure and function can occur at an early age 2, 3. Flexible bronchoscopy with bronchoalveolar lavage (BAL) has allowed detection of both respiratory pathogens and inflammation in the lower airways of asymptomatic CF infants as young as 2-weeks 4. Recently, some CF infants were found to have airway inflammation without respiratory pathogens being detected 5, 6. This led to speculation that the basic defect in CF itself may initiate inflammation 5–7. However, in Melbourne, Australia, the authors were unable to confirm these observations 8. Instead it wasfound that increasing bacterial numbers were associated with elevated inflammatory indices. Nevertheless, this was not a linear relationship, since inflammation increased significantly only after bacterial numbers reached 1x105 colony forming units (cfu)·mL–1 9. Although BAL is routinely performed in both lungs and the samples pooled for analysis, most BAL studies in CF children sample from a single lobe, usually the lingula 5, 6, 10, 11. The authors hypothesized that sampling from a single lobe may fail to detect pathogens elsewhere in the lungs. By collecting samples from both lungs, and performing a separate analysis, it was determined whether BAL findings from a single lobe might be generalized to other regions.


   Methods
TOP
 Abstract
 Methods
Results
 Discussion
 Acknowledgements
 References
 
Subjects
Since 1989 the state of Victoria, Australia has had a newborn CF screening programme 12. The diagnosis is confirmed by either establishing homozygosity for the {Delta}F508 mutation or by sweat chloride concentrations ≥60 mmol·L–1. All patients are managed by the Department of Respiratory Medicine at the Royal Children's Hospital, Melbourne.

From 1990, newly diagnosed infants were eligible for recruitment into a longitudinal population-based investigation of early CF lung disease 4, 8, 9. Subjects underwent an initial, and then an annual, BAL tocollect lower respiratory secretions. The Royal Children's Hospital Ethics in Human Research Committee approved the study and written informed consent was obtained from the parents or guardian of each child before bronchoscopy.

During an eight-month period, 33 consecutive CF infants and young children undergoing bronchoscopy as part of the longitudinal study were enrolled. None were receiving intravenous antibiotics or anti-inflammatory agents and seven (21%) were newly diagnosed CF subjects having their first bronchoscopy.

In the infant CF patient population in the present study, BAL specimens pooled from both lungs have increased inflammatory indices when bacterial counts are ≥1x105 cfu·mL–1 9. This diagnostic threshold was used to place subjects into one of two groups for further analysis. The clinical characteristics of the study participants are given in table 1Go. Although subjects with ≥1x105 cfu·mL–1 were older, differences between the two groups were generally minor and not statistically significant.


View this table:
[in this window]
[in a new window]
  		Table 1— The clinical characteristics of the study participants

 
Bronchoalveolar lavage
BAL was performed under general anaesthesia. Following application of topical lignocaine a flexible bronchoscope (Olympus model BF3 C20, external diameter 3.6 mm, suction channel 1.2 mm; Olympus Corporation of America, Hyde Park, NY, USA) was introduced into the lower airway through a laryngeal mask, avoiding the use of the suction channel until the tip of the bronchoscope was below the carina 8, 9. In random order, the tip was first wedged into either the right middle lobe or lingula bronchus. To optimize sampling from endobronchial sites a single small volume lavage was performed by instilling 1 mL·kg–1 (maximum 20 mL) of sterile, nonbacteriostatic normal saline at room temperature through the suction channel over 2–3 s. The saline was immediately aspirated into a sterile suction set over 10–20 s using negative pressures of 100–150 mmHg. The bronchoscope tip was wedged into the opposite bronchus next where a further single volume lavage was performed.

After induction of anaesthesia and before application of topical lignocaine to the vocal cords, a cotton-tipped swab was swept over the posterior oropharynx, tonsils and fauces. Blood was collected by venepuncture and allowed to clot at room temperature. The BAL fluid specimens from each lobe were kept separate and immediately transported on ice to the laboratory for processing.

Microbiology
As previously described 8, 9, 500 µL of BAL fluid was serially diluted onto six different media (horse blood, mannitol salt, MacConkey, chocolate bacitracin, cetrimide, and Burkholderia cepacia selective agar) for quantitative bacteriology, giving a lower detection limit of 1x101 cfu·mL–1. Oropharyngeal swabs were streaked onto the same media. Subjects with respiratory symptoms also had their BAL and nasopharyngeal aspirates tested for respiratory viruses by direct fluorescent labelled antibodies and culture 13. Respiratory bacterial pathogens were identified as Staphylococcus aureus, Haemophilus influenzae, Pseudomonas aeruginosa, Moraxella catarrhalis, Streptococcus pneumoniae, Burkholderia cepacia or Stenotrophomonas maltophilia. In contrast, Neisseria species, {alpha} haemolytic streptococci, Haemophilus (non-influenzae) species, diphtheroids and coagulase negative staphylococci were judged to be upper respiratory flora.

Cytology and cytokine levels
Total cell counts were determined on 100 µL of uncentrifuged BAL fluid using a Neubauer haemocytometer counting chamber (Weber, Teddington, UK). Differential cell counts were estimated after centrifugation of a 300 µL aliquot of BAL fluid at 72 g for 5 min in a Cytospin-2-cytocentrifuge (Shandon Southern Instruments, Sewick, PA, USA), Wright-Giemsa staining and counting cells at magnification under oil x1,000. The clotted blood and BAL fluid were centrifuged at 500 g for 5-min at 4°C and the supernatant immediately stored at –70°C until the time of testing. The neutrophil chemokine interleukin (IL)-8 was measured by a double-sandwich, monoclonal enzyme immunoabsorbent assay which determined free and receptor bound IL-8 (Medgenix Diagnostics, Fleurus, Belgium). The assay detection limit was 0.7 pg·mL–1.

As several studies report that urea and albumin diffuse into BAL fluid during bronchoscopy and inflammatory states leading to overestimation of epithelial lining fluid volume 14, results are reported per mL of BAL fluid.

Statistical analysis
Data analysis was performed using Minitab Release 12 (Minitab Inc., State College, PA, USA). Pathogen and cell counts (per mL), and IL-8 concentrations, had strongly skewed distributions; following standard practice these were logarithmically transformed to approximate normality and summarized as geometric means with 95% confidence intervals (CI). Lymphocyte subset percentages were approximately symmetrically distributed and analysed without transformation. Within and between group comparisons for continuous variables were conducted using paired and two-sample t-tests respectively (in the log scale where appropriate). Proportions were compared by Chi-squared tests and associations between bacterial count, neutrophils and IL-8 were assessed using Spearman correlation.


   Results
TOP
 Abstract
 Methods
 Results
Discussion
 Acknowledgements
 References
 
The results for each of the nine CF infants with ≥1x105 cfu·mL–1 in their BAL fluid are shown in table 2Go. While BAL samples from three subjects had bacterial counts ≥1x105 cfu·mL–1 from both lobes, another six had these pathogen numbers confined to the right middle lobe. In four subjects (numbers 1, 2, 3 and 5) there were large differences in bacterial load between the two sample sites. Except for subject 2, the nine infants had single pathogenic bacterial species detected in their BAL fluid cultures. Bacterial concordance between the lobes was observed in seven of the nine subjects and all, except subject 6, had the same pathogens isolated from both BAL and oropharyngeal cultures.


View this table:
[in this window]
[in a new window]
  		Table 2— Cystic fibrosis subjects with ≥1x105 cfu·mL–1 of bacteria in their bronchalveolar lavage

 
Thirty subjects had upper respiratory flora identified in at least one of their BAL cultures. The geometric mean colony counts of these nonpathogenic bacteria were similar in both right middle and lingula BAL specimens (4.5 versus 2.7x102 cfu·mL–1 respectively) and did not vary with sample order. In contrast, respiratory viruses were not detected.

The right middle lobe was first in BAL sample order for 16 (48%) subjects. Overall, there were no differences in sample volumes between the two lobes. The mean (standard deviation (sd); range) volume and mean percentage recovery BAL fluid values from both the right middle and lingula lobes were 7.2 (4.4; 1–18) versus 7.9 (4.6; 1–19) mL and 41.9 (15.9; 15–75)% versus 43.7 (15.7; 17–75)% respectively. BAL profiles from the six CF infants with ≥1x105 cfu·mL–1 detected only in their right middle lobes and the 24 CF subjects with <1x105 cfu·mL–1 are presented in table 3Go. The BAL fluid inflammatory indices were elevated in both lobes from subjects with unilateral pathogen counts ≥1x105 cfu·mL–1. Significant differences in selected right middle lobe inflammatory markers were present when these subjects were compared with infants whose counts were <1x105 cfu·mL–1. Similar differences were observed, reaching significance for IL-8, when the BAL inflammatory indices within the lingula lobes of the two groups were compared.


View this table:
[in this window]
[in a new window]
  		Table 3— Cystic fibrosis infant bronchoalveolar lavage profiles from the right middle and lingula lobes

 
For all 33 subjects, right middle lobe bacterial pathogen numbers were significantly correlated with right middle lobe and lingula neutrophils (r=0.55; p<0.01 versus r=0.41; p<0.05) and IL-8 (r=0.35; p<0.05 versus r=0.55; p<0.01) values respectively. In contrast, numbers of pathogenic bacteria in the lingula correlated with the right middle lobe neutrophils (r=0.44; p<0.01) and lingula IL-8 concentrations only (r=0.37; p<0.05).

Although the IL-8 concentration in several BAL samples was elevated, serum IL-8 levels remained low (range 3.3–8.1 pg·mL–1) and there was no correlation between serum IL-8 concentrations and pathogen numbers in BAL fluid.


   Discussion
TOP
 Abstract
 Methods
 Results
 Discussion
Acknowledgements
 References
 
This study suggests that BAL findings from single lobes of CF infants may not represent changes found elsewhere within their lungs. While bacterial numbers can be unequally distributed, airway inflammation seems more pervasive. This may explain why single lobe BAL studies report some CF infants have inflammation in the absence of detectable organisms. Therefore, when performing BAL to study airway infection and inflammation in CF children, more than one site should be sampled.

Previous studies have reported that regional differences in disease parameters exist within CF lungs. Airway surface liquid composition varies between upper and lower airway sites 15 and lung pathology proceeds at variable rates with several regions injured at different times. This is supported by high-resolution computed tomography in CF infants showing bronchiectasis most commonly involves the upper lobes, particularly in the right lung 2. These more severe changes within the upper lobes persist into adulthood 16, and are confirmed at autopsy 17.

Post mortem studies in adults have also shown that bacteria are not uniformly distributed throughout the CF lung 18. Mucoid P. aeruginosa are abundant in the bronchioles, at sites of active inflammation and obliterative changes, but absent from areas of fibrosis or relatively well-preserved lung tissue 19. Regional variations in bacterial load were recently reported in 12 stable adult CF patients 20. All had 1x105–1x108 cfu·mL–1 of P. aeruginosa or S. aureus in BAL specimens from the right upper lobe. In contrast, these bacteria were not detected in the right middle or lower lobe samples of six subjects. However, inflammation was present in the upper lobes and also in lung segments where bacteria were absent or detected in lesser quantities. These findings are consistent with the data from the present study.

Why inflammation should develop within lung segments of a small number of subjects where bacteria cannot be grown by the usual culture techniques is unknown. This may result from bacteria being present in reduced numbers detectable only by molecular techniques or from persistence of products such as lipopolysaccharide 20, 21. Others have observed a nonlinear relationship between bacterial load and airway inflammation 9, 22, and this suggests that inflammatory changes without detectable respiratory pathogens may be from a previously resolved infection 8.

There is also evidence for a more generalized airway inflammatory response to focal bacteria within the lung 20. In a rat model of P. aeruginosa infection, installation of bacteria into the right lung resulted in local inflammation and cytokine release 23. However, when large inocula were deployed, plasma cytokine levels increased and inflammatory changes developed in the opposite lung. Adult patients with severe unilateral pneumonia have raised cytokine concentrations in BAL specimens from the noninvolved lung 24. Correlation between bacterial numbers in the right middle lobe and inflammation in the lingula suggests that systemic factors may influence local responses. Whether a critical threshold above which bacteria alter the integrity of the alveolar epithelial barrier, disrupting the compartmentalization of inflammatory mediators 25, is important in CF is uncertain. An association between serum IL-8 levels and bacterial numbers or inflammation was not observed. While studies in older CF patients with chronic lung disease report modest elevations of circulating inflammatory mediators 26, 27, these may only represent increased local production of cytokines and may not be of any pathophysiological significance.

Although quantitative bacteriology and a diagnostic threshold of ≥1x105 cfu·mL–1 of pathogenic bacteria in CF children adjusts for potential upper airway contamination 9, this might not identify individuals with developing or partially treated infections or discriminate between resolving infection and other causes of airway inflammation. The concordant and increased bacterial numbers in the lingula BAL fluid from subjects l, 4 and 6 suggest that infection may have been present in this lobe too. While this might explain some of the observations, subjects 2, 3, and 5 had large differences in bacterial numbers between the two lobes, but inflammatory changes remained at each of these sites.

Prospective recruitment of CF infants diagnosed by a newborn screening program allows the early detection of lung disease in an unselected population. As expected in this young study population, only 27% had large numbers of bacteria within their lower airways. The predominance of the right middle lobe as a site for bacteria might therefore, have arisen by sampling error or chance alone. However, the sampling order, percentage BAL returns and oropharyngeal flora counts were comparable between both groups of subjects. Significant contamination of the second BAL sample by remnants of the first sample within the bronchoscope seems unlikely, as there were no apparent order effects for either upper respiratory flora or pathogenic bacteria colony counts. Employing a relatively large aliquot of BAL fluid for culture, and using several plates containing selective or nonselective media reduced the risk of microbiological sampling errors. Similarly, using a single small volume bronchial lavage optimized the detection of endobronchial organisms and airway inflammation 28.

In the present study, nonbacterial causes of lingula inflammation seem unlikely. Aspiration from gastro-oesophageal reflux most commonly involves the upper lobes 29, while the lingula is the least likely lobe to show bronchiectasis 2. However, neither pH monitoring nor examination of BAL specimens for fat laden alveolar macrophages was undertaken.

To conclude, this observational study suggests that bacterial numbers within some infant cystic fibrosis lungs may not be uniform. In contrast signs of airway inflammation may be detected in more than one lobe. These findings are supported by experimental animal models and clinical and post mortem studies in adult cyctic fibrosis subjects. Bronchoalveolar lavage microbiological results from a single lobe may not therefore, always represent findings in other regions of the lungs. This could explain why some infant single lobe bronchoalveolar lavage studies have reported inflammation in the absence of detectable respiratory pathogens. It emphasizes the importance of sampling from multiple lung segments or lobes when using bronchoalveolar lavage to study cystic fibrosis lung disease.


   Acknowledgements
TOP
 Abstract
 Methods
 Results
 Discussion
 Acknowledgements
References
 
The authors gratefully acknowledge the support of K. Brown and the staff of the Anaesthetic Dept of the Royal Children's Hospital for their continued support of this project.


   References
TOP
 Abstract
 Methods
 Results
 Discussion
 Acknowledgements
 References
 

  1. McGrath SA, Basu A, Zeitlin PL. Cystic fibrosis gene and protein expression during fetal lung development. Am J Respir Cell Mol Biol 1993;8:201–208.
  2. Stiglbauer R, Schurawitzki H, Eichler I, Vergesslich KA, Götz M. High-resolution CT in children with cystic fibrosis. Acta Radiologica 1992;33:548–553.[Web of Science][Medline] [Order article via Infotrieve]
  3. Tepper RS, Montgomery GL, Ackerman V, Eigen H. Longitudinal evaluation of pulmonary function in infants and very young children with cystic fibrosis. Pediatr Pulmonol 1993;16:96–100.[Medline] [Order article via Infotrieve]
  4. Armstrong DS, Grimwood K, Carzino R, Carlin JB, Olinsky A, Phelan PD. Lower respiratory infection and inflammation in infants with newly diagnosed cystic fibrosis. BMJ 1995;310:1571–1572.[Free Full Text]
  5. Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DWH. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995;151:1075–1082.[Abstract]
  6. Balough K, McCubbin M, Weinberger M, Smits W, Aherns R, Fick R. The relationship between infection and inflammation in the early stages of lung disease from cystic fibrosis. Pediatr Pulmonol 1995;20:63–70.[Web of Science][Medline] [Order article via Infotrieve]
  7. Cantin A. Cystic fibrosis lung inflammation: early, sustained, and severe. Am J Respir Crit Care Med 1995;151:939–941.[Web of Science][Medline] [Order article via Infotrieve]
  8. Armstrong DS, Grimwood K, Carlin JB, et al. Lower airway inflammation in infants and young children with cystic fibrosis. Am J Respir Crit Care Med 1997;156:1197–1204.[Abstract/Free Full Text]
  9. Armstrong DS, Grimwood K, Carlin JB, Carzino R, Olinsky A, Phelan PD. Bronchoalveolar lavage or oropharyngeal cultures to identify lower respiratory pathogens in infants with cystic fibrosis. Pediatr Pulmonol 1996;21:267–275.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  10. Wilmott RW, Kassab JT, Kilian PL, Benjamin WR, Douglas SR, Wood RE. Increased levels of interleukin-1 in bronchoalveolar washings from children with bacterial pulmonary infections. Am Rev Respir Dis 1990;142:365–368.[Web of Science][Medline] [Order article via Infotrieve]
  11. Birrer P, McElvaney NG, Rudeberg A, et al. Protease-antiprotease imbalance in the lungs of children with cystic fibrosis. Am J Respir Crit Care Med 1994;150:207–213.[Abstract]
  12. Massie RJ, Olsen M, Glazner J, Robertson CF, Francis I. Newborn screening for cystic fibrosis in Victoria: 10 years' experience (1989–1998). Med J Aust 2000;172:584–587.[Web of Science][Medline] [Order article via Infotrieve]
  13. Armstrong D, Grimwood K, Carlin J, et al. Severe viral respiratory infections in infants with cystic fibrosis. Pediatr Pulmonol 1998;26:371–379.[CrossRef][Medline] [Order article via Infotrieve]
  14. Walters EH, Gardiner PV. Bronchoalveolar lavage as a research tool. Thorax 1991;46:613–618.[Free Full Text]
  15. Hull J, Skinner W, Robertson C, Phelan P. Elemental content of airway surface liquid from infants with cystic fibrosis. Am J Respir Crit Care Med 1998;157:10–14.
  16. Maffessanti MD, Candusso M, Brizzi F, Piovesana F. Cystic fibrosis in children: HRCT findings and distribution of disease. J Thorac Imag 1996;11:27–38.[Web of Science][Medline] [Order article via Infotrieve]
  17. Tomashefski JF, Bruce M, Goldberg HI, Dearborn DG. Regional distribution of macroscopic lung disease in cystic fibrosis. Am Rev Respir Dis 1986;133:535–540.[Web of Science][Medline] [Order article via Infotrieve]
  18. Smith DL, Smith EG, Pitt TL, Stableforth DE. Regional microbiology of the cystic fibrosis lung: a post-mortem study in adults. J Infection 1998;37:41–43.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  19. Baltimore RS, Christie CDC, Walker-Smith GJ. Immunohistopathologic localization of Pseudomonas aeruginosa in lungs from patients with cystic fibrosis. Am Rev Respir Dis 1989;140:1650–1661.[Web of Science][Medline] [Order article via Infotrieve]
  20. Meyer KC, Sharma A, Rosenthal NS, Peterson K, Brennan L. Regional variability of lung inflammation in cystic fibrosis. Am J Respir Crit Care Med 1997;156:1536–1540.[Abstract/Free Full Text]
  21. Copenhaver S, Sage A, Vasil A, et al. BALF PCR and ELISA identification on non-culturable Pseudomonas aeruginosa in infants and toddlers with cystic fibrosis. Pediatr Pulmonol 1996;22:Suppl. 13291–292.
  22. Muhlebach MS, Stewart PW, Leigh MW, Noah TL. Quantitation of inflammatory responses to bacteria in young cystic fibrosis and control patients. Am J Respir Crit Care Med 1999;160:186–191.[Abstract/Free Full Text]
  23. Terashima T, Matsubara H, Nakamura M, et al. Local Pseudomonas installation induces contralateral lung injury and plasma cytokines. Am J Respir Crit Care Med 1996;153:1600–1605.[Abstract]
  24. Headley AS, Tolley E, Meduri GU. Infections and the inflammatory response in acute respiratory distress syndrome. Chest 1997;111:1306–1321.[Abstract/Free Full Text]
  25. Tutor JD, Mason CM, Dobard E, Beckerman RC, Summer WS, Nelson S. Loss of compartmentalization of alveolar tumor necrosis factor after lung injury. Am J Respir Crit Care Med 1994;149:1107–1111.[Abstract]
  26. Wilmott RW, Frenzke M, Kociela V, Peng L. Plasma interleukin-l{alpha} and ß, tumor necrosis factor-{alpha}, and lipopolysaccharide concentrations during pulmonary exacerbations of cystic fibrosis. Pediatr Pulmonol 1994;18:21–27.[Medline] [Order article via Infotrieve]
  27. Nixon LS, Yung B, Bell SC, Elborn JS, Shale DJ. Circulating immunoreactive interleukin-6 in cystic fibrosis. Am J Respir Crit Care Med 1998;157:1764–1769.
  28. Ratjen F, Rietschel E, Griese M, Ballmann M, Kleinau I, Doring G, Reinhardt D, Paul K, for the bronchoalveolar lavage for the evaluation of anti-inflammatory treatment (BEAT) study group. Fractional analysis of bronchoalveolar lavage fluid cytology in cystic fibrosis patients with normal lung function. Eur Respir J 2000;15:141–145.[Abstract]
  29. Button BM, Heine RG, Catto-Smith AG, Phelan PD, Olinsky A. Postural drainage and gastro-oesophageal reflux in infants with cystic fibrosis. Arch Dis Child 1997;76:148–150.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Am. J. Respir. Crit. Care Med.Home page
P. D. Sly, S. Brennan, C. Gangell, N. de Klerk, C. Murray, L. Mott, S. M. Stick, P. J. Robinson, C. F. Robertson, S. C. Ranganathan, et al.
Lung Disease at Diagnosis in Infants with Cystic Fibrosis Detected by Newborn Screening
Am. J. Respir. Crit. Care Med., July 15, 2009; 180(2): 146 - 152.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
T. A. Douglas, S. Brennan, S. Gard, L. Berry, C. Gangell, S. M. Stick, B. S. Clements, and P. D. Sly
Acquisition and eradication of P. aeruginosa in young children with cystic fibrosis
Eur. Respir. J., February 1, 2009; 33(2): 305 - 311.
[Abstract] [Full Text] [PDF]

Home page
 Lab AnimHome page
I Kukavica-Ibrulj and R C Levesque
Animal models of chronic lung infection with Pseudomonas aeruginosa: useful tools for cystic fibrosis studies
Lab Anim, October 1, 2008; 42(4): 389 - 412.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
M. Griese, M. Kappler, A. Gaggar, and D. Hartl
Inhibition of airway proteases in cystic fibrosis lung disease
Eur. Respir. J., September 1, 2008; 32(3): 783 - 795.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
S. D. Davis, A. S. Brody, M. J. Emond, L. C. Brumback, and M. Rosenfeld
Endpoints for Clinical Trials in Young Children with Cystic Fibrosis
Proceedings of the ATS, August 1, 2007; 4(4): 418 - 430.
[Abstract] [Full Text] [PDF]

Home page
 Proc R Soc BHome page
F. Harrison and A. Buckling
High relatedness selects against hypermutability in bacterial metapopulations
Proc R Soc B, May 22, 2007; 274(1615): 1341 - 1347.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
S. D. Davis, L. A. Fordham, A. S. Brody, T. L. Noah, G. Z. Retsch-Bogart, B. F. Qaqish, B. C. Yankaskas, R. C. Johnson, and M. W. Leigh
Computed Tomography Reflects Lower Airway Inflammation and Tracks Changes in Early Cystic Fibrosis
Am. J. Respir. Crit. Care Med., May 1, 2007; 175(9): 943 - 950.
[Abstract] [Full Text] [PDF]

Home page
 MicrobiologyHome page
F. Harrison
Microbial ecology of the cystic fibrosis lung
Microbiology, April 1, 2007; 153(4): 917 - 923.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
T. D. Starner and P. B. McCray Jr.
Pathogenesis of Early Lung Disease in Cystic Fibrosis: A Window of Opportunity To Eradicate Bacteria
Ann Intern Med, December 6, 2005; 143(11): 816 - 822.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
K. Paul, E. Rietschel, M. Ballmann, M. Griese, D. Worlitzsch, J. Shute, C. Chen, T. Schink, G. Doring, S. van Koningsbruggen, et al.
Effect of Treatment with Dornase Alpha on Airway Inflammation in Patients with Cystic Fibrosis
Am. J. Respir. Crit. Care Med., March 15, 2004; 169(6): 719 - 725.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
D. S. Armstrong
In Celebration of Expectoration: Induced Sputum Indices as Outcome Measures in Cystic Fibrosis
Am. J. Respir. Crit. Care Med., December 15, 2003; 168(12): 1412 - 1413.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
R. L. Gibson, J. L. Burns, and B. W. Ramsey
Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis
Am. J. Respir. Crit. Care Med., October 15, 2003; 168(8): 918 - 951.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
A B Chang, N C Boyce, I B Masters, P J Torzillo, and J P Masel
Bronchoscopic findings in children with non-cystic fibrosis chronic suppurative lung disease
Thorax, November 1, 2002; 57(11): 935 - 938.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (27)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gutierrez, J.P.
Right arrow Articles by Phelan, P.D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gutierrez, J.P.
Right arrow Articles by Phelan, P.D.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS